Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387283 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
A Phase 1 study, sponsored by Sarepta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00387283 is a Phase 1 study that has completed, run by Sarepta Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT00387283, a Phase 1 study, has completed, sponsored by Sarepta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
During a clinical study of people with severe West Nile virus infections, it was determined that the drug AVI-4020 crossed the blood-brain barrier. This study will assess the amount of drug that goes across the blood-brain barrier and the drug levels measured in both the blood and urine. The objective of this study is to find out how much and how fast this drug crosses this barrier.
Interventions
- DRUG AVI-4020 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387283
The ClinicalTrials.gov registry entry for NCT00387283 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVI-4020 Injection is the first listed.
NCT00387283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387283 about?
NCT00387283 is a clinical study titled "Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020". During a clinical study of people with severe West Nile virus infections, it was determined that the drug AVI-4020 crossed the blood-brain barrier. This study will assess the amount of drug that goes across the blood-brain barrier and the drug levels measured in both the blood and urine. The object...
What is the current status of trial NCT00387283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-10. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00387283?
The interventions under investigation include: AVI-4020 Injection (DRUG).
Who is sponsoring clinical trial NCT00387283?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.